Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy: The ACOSOG Z1041 (Alliance) Randomized Clinical Trial.

Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy: The ACOSOG Z1041 (Alliance) Randomized Clinical Trial. JAMA Oncol. 2019 01 01; 5(1):45-50.

View in: PubMed

subject areas

Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
Biomarkers, Tumor
Breast Neoplasms
Chemotherapy, Adjuvant
Cyclophosphamide
Disease Progression
Drug Administration Schedule
Epirubicin
Female
Fluorouracil
Humans
Middle Aged
Neoadjuvant Therapy
Paclitaxel
Puerto Rico
Receptor, ErbB-2
Risk Factors
Time Factors
Trastuzumab
United States

authors with profiles

KELLY K HUNT
AMAN U BUZDAR
FUNDA MERIC-BERNSTAM